Page 76 - 2019_12-Haematologica-web

T. Raskovalova et al.
tic syndromes in patients with unexplained
cytopenias: a retrospective study of 322 bone marrows. Leuk Res. 2009;33(10):1313- 1318.
7. Cherian S, Moore J, Bantly A, et al. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom. 2005;64(1):9-17.
8. Cherian S, Moore J, Bantly A, et al. Flow- cytometric analysis of peripheral blood neu- trophils: a simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes. Am J Hematol. 2005;79(3):243- 245.
9. Rashidi HH, Xu X, Wang HY, et al. Utility of peripheral blood flow cytometry in differen- tiating low grade versus high grade myelodysplastic syndromes (MDS) and in the evaluation of cytopenias. Int J Clin Exp Pathol. 2012;5(3):224-230.
10. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-536.
11. Germing U, Strupp C, Giagounidis A, et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Dusseldorf Registry on myelodysplastic syndromes. Leuk Res. 2012;36(6):727-734.
12. Hast R, Nilsson I, Widell S, et al. Diagnostic significance of dysplastic features of periph- eral blood polymorphs in myelodysplastic syndromes. Leuk Res. 1989;13(2):173-178.
13. Widell S, Hellstrom-Lindberg E, Kock Y, et al. Peripheral blood neutrophil morphology reflects bone marrow dysplasia in myelodysplastic syndromes. Am J Hematol. 1995;49(2):115-120.
14. Odobasic D, Kitching AR, Holdsworth SR. Neutrophil-Mediated Regulation of Innate and Adaptive Immunity: The Role of Myeloperoxidase. J Immunol Res. 2016; 2016:2349817.
15. Elghetany MT, Peterson B, MacCallum J, et al. Deficiency of neutrophilic granule mem- brane glycoproteins in the myelodysplastic syndromes: a common deficiency in 216 patients studied by the Cancer and Leukemia Group B. Leuk Res. 1997;21(9): 801-806.
16. Vikentiou M, Psarra K, Kapsimali V, et al.
Distinct neutrophil subpopulations pheno- type by flow cytometry in myelodysplastic syndromes. Leuk Lymphoma. 2009; 50(3):401-409.
17. Sackett DL, Haynes RB. The architecture of diagnostic research. BMJ. 2002;324(7336): 539-541.
18. Greenberg PL, Tuechler H, Schanz J, et al. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syn- dromes. Blood. 2016;128(16):2096-2097.
19. BD FACSDiva Software 6.0 Reference Manual, 2007.
20. Shapiro HM. Practical flow cytometry. 4th ed. Hoboken: John Wiley & Sons, 2003;736. 21. Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw.
2017;15(1):60-87.
22. Valent P, Bain BJ, Bennett JM, et al.
Idiopathic cytopenia of undetermined sig- nificance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their dis- tinction from low risk MDS. Leuk Res. 2012;36(1):1-5.
23. Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017;8(43):73483-73500.
24. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating char- acteristic (ROC) curve. Radiology. 1982;143(1):29-36.
25. Davis BH, McLaren CE, Carcio AJ, et al. Determination of optimal replicate number for validation of imprecision using fluores- cence cell-based assays: proposed practical method. Cytometry B Clin Cytom. 2013;84(5):329-337.
26. Ticchioni M, Brouzes C, Durrieu F, et al. Acceptable "real-life" variability for lympho- cyte counts by flow cytometry. Cytometry B Clin Cytom. 2018 Dec 7. [Epub ahead of print]
27. Wood B, Jevremovic D, Bene MC, et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part V - assay performance criteria. Cytometry B Clin Cytom. 2013;84(5):315- 323.
28. Pewsner D, Battaglia M, Minder C, et al.
Ruling a diagnosis in or out with "SpPIn" and "SnNOut": a note of caution. BMJ. 2004;329(7459):209-213.
29. Porwit A, van de Loosdrecht AA, Bettelheim P, et al. Revisiting guidelines for integration of flow cytometry results in the WHO clas- sification of myelodysplastic syndromes- proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia. 2014; 28(9):1793-1798.
30. Tang G, Jorgensen LJ, Zhou Y, et al. Multi- color CD34(+) progenitor-focused flow cytometric assay in evaluation of myelodys- plastic syndromes in patients with post can- cer therapy cytopenia. Leuk Res. 2012;36 (8):974-981.
31. Hast R, Eriksson M, Widell S, et al. Neutrophil dysplasia is not a specific feature of the abnormal chromosomal clone in myelodysplastic syndromes. Leuk Res. 1999;23(6):579-584.
32. Solly F, Rigollet L, Baseggio L, et al. Comparable flow cytometry data can be obtained with two types of instruments, Canto II, and Navios. A GEIL study. Cytometry A. 2013;83(12):1066-1072.
33. Manion EM, Rosenthal NS. Bone marrow biopsies in patients 85 years or older. Am J Clin Pathol. 2008;130(5):832-835.
34. Brunetti GA, Tendas A, Meloni E, et al. Pain and anxiety associated with bone marrow aspiration and biopsy: a prospective study on 152 Italian patients with hematological malignancies. Ann Hematol. 2011;90(10): 1233-1235.
35. Hjortholm N, Jaddini E, Halaburda K, et al. Strategies of pain reduction during the bone marrow biopsy. Ann Hematol. 2013;92(2): 145-149.
36. Berenson JR, Yellin O, Blumenstein B, et al. Using a powered bone marrow biopsy sys- tem results in shorter procedures, causes less residual pain to adult patients, and yields larger specimens. Diagn Pathol. 2011;6:23.
37. Bain BJ. Morbidity associated with bone marrow aspiration and trephine biopsy - a review of UK data for 2004. Haematologica. 2006;91(9):1293-1294.
38. de Groot JA, Bossuyt PM, Reitsma JB, et al. Verification problems in diagnostic accuracy studies: consequences and solutions. BMJ. 2011;343:d4770.
2390
haematologica | 2019; 104(12)